U.S. Stem Cell, Inc. (USRM)

Market Cap	642.00
Revenue (ttm)	19,974
Net Income (ttm)	-567,311
Shares Out	6.42M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	88,944
Open	n/a
Previous Close	0.0001
Day's Range	n/a
52-Week Range	n/a
Beta	-1.28
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About USRM

U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-der...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 15, 2008
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: USRM

Financial Performance

In 2022, U.S. Stem Cell's revenue was $82,049, a decrease of -59.13% compared to the previous year's $200,749. Losses were -$3.31 million, -22.91% less than in 2021.